Here’s what we’ll cover today: We’ll break down this MFN policy and what it means for you, look at Hungary’s cautionary tale, and dig into the data behind drug pricing in the U.S. and beyond. We’ll hear from experts, share a couple of real-life stories, and explore different perspectives—some folks think this policy is a bold move, while others see it as a risky gamble. Plus, I’ll leave you with practical tips to save on medications, no matter what happens with this policy. So, grab a cup of tea or coffee, get comfortable, and let’s get started on this journey to understand how we can keep our medications affordable and accessible. Ready? Let’s go!
Today’s episode draws from an opinion piece by a Hungarian author, published via NewsNow, that critiques President Trump’s May 2025 executive order on Most Favored Nation (MFN) drug pricing. This policy aims to lower U.S. drug prices by tying them to the lowest prices paid by comparable developed nations, like those in Europe. The author argues that Hungary tried a similar approach with a blind bidding system and voluntary price caps pegged to the cheapest European Economic Area prices, but it backfired. Despite appearing affordable, Hungary’s drug prices are high relative to its GDP per capita, and the country faces frequent drug shortages—one of the worst in the EU. This forces many Hungarians, including the author, to seek medications abroad when pharmacies run dry.